MeiraGTx

#Business #Eli Lilly #MeiraGTx #Ophthalmology

MeiraGTx partners with Eli Lilly in ophthalmology 

Genetic medicines company MeiraGTx has announced a strategic partnership with Eli Lilly to develop and commercialise genetic medicines in ophthalmology.  The deal, worth $475 million, will see MeiraGTx grant Lilly worldwide exclusive rights to its AAV-AIPL1 programme for treatment of Leber congenital amaurosis 4 (LCA4). LCA4 is one of the… Read More

#Business & Investment #News

Child having an eye test
#Gene therapy #Genetic diseases #MeiraGTx #Ophthalmology #UCL

Gene therapy treats rare genetic sight impairment in the UK

Four young children have gained improvements in their vision following treatment with a new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology, with the support of MeiraGTx.  The children were born with a severe impairment to their sight due to a rare genetic deficiency… Read More

#News #Trending News